Posted by Michael Wonder on 22 Dec 2024
Givinostat conditionally approved to treat patients with Duchenne muscular dystrophy
20 December 2024 - The MHRA has today granted a conditional marketing authorisation for the medicine givinostat (Duvyzat) to treat Duchenne muscular dystrophy.
Givinostat is a non-steroidal drug indicated for the treatment of patients aged 6 years of age and older with all genetic variants of Duchenne muscular dystrophy.
